Prof. Chan Wai-yee has recently been appointed as a Non-official Director of the Hong Kong Genome Institute (HKGI) for a term of two years from 5 November 2020.

The HKGI is a newly established private company limited by guarantee and wholly owned by the Government of the Hong Kong Special Administrative Region (HKSAR) with an aim of implementing the Hong Kong Genome Project (HKGP). The HKGP is a large-scale genome sequencing project, with the pilot phase focusing on patients and their family members with undiagnosed disorders and hereditary cancers, under which 40,000 to 50,000 genomes would be sequenced to aid diagnoses or clinical management. The appointment not only recognises Prof. Chan’s exceptional academic standing but also his remarkable contributions to the field of genetic research.

The related press release by the HKSAR Government can be viewed HERE.

陳偉儀教授近日獲委任為香港基因組中心非官方董事，兩年任期由2020年11月5日展開。

香港基因組中心是新成立的私人擔保有限公司，由香港特別行政區政府全資擁有，旨在推行香港基因組計劃。香港基因組計劃是一項大型基因組測序計劃，先導階段聚焦患有未能確診的病症，以及與遺傳有關的癌症的病人和其家屬。計劃會為四萬至五萬個基因組進行測序，結果將有助於診斷或臨牀治療。以上委任肯定陳教授的傑出學術地位及在基因研究領域的貢獻。

請按此處瀏覽香港特別行政區政府的有關新聞公報。

陈伟仪教授近日获委任为香港基因组中心非官方董事，两年任期由2020年11月5日展开。

香港基因组中心是新成立的私人担保有限公司，由香港特别行政区政府全资拥有，旨在推行香港基因组计划。香港基因组计划是一项大型基因组测序计划，先导阶段聚焦患有未能确诊的病症，以及与遗传有关的癌症的病人和其家属。计划会为四万至五万个基因组进行测序，结果将有助于诊断或临床治疗。以上委任肯定陈教授的杰出学术地位及在基因研究领域的贡献。

请按此处浏览香港特别行政区政府的有关新闻公报。